Literature DB >> 21158893

Prospective echocardiographic evaluation of patients with endogenous subclinical hyperthyroidism and after restoring euthyroidism.

Grzegorz Kaminski1, Dariusz Michalkiewicz, Karol Makowski, Zbigniew Podgajny, Norbert Szalus, Marek Ruchala, Ewelina Szczepanek, Grzegorz Gielerak.   

Abstract

OBJECTIVES: Clinical significance of, and the need for, treatment in subclinical hyperthyroidism (sHT) is still a matter of debate. The aim of the study was to assess the impact of sHT on echocardiographic parameters.
DESIGN: Patients with endogenous sHT of nonautoimmune origin underwent full echocardiographic assessment at diagnosis and after restoring euthyroidism with radioiodine treatment. PATIENTS: Studied group consisted of 44 patients (37 women, 7 men), aged 22-65 years (mean 45·9±11·0). MEASUREMENTS: Full echocardiographic assessment included estimation of cardiac chamber diameters and volume as well as cardiac contractility, according to the guidelines of the American Society of Echocardiography. Left ventricular mass was calculated according to Penn's convention. For estimation of left ventricle diastolic function, the following echocardiographic parameters were obtained: maximal early filling wave velocity (E), maximal late filling wave velocity (A), E/A ratio, isovolumetric relaxation time and early filling wave deceleration time.
RESULTS: In the studied group, phase of sHT was associated with increased volume of heart chambers, increased diameter of ascending aorta, increased left ventricle mass and disturbed left ventricle relaxation (P<0·05). The systolic function of the left ventricle was unaffected; however, the ejection time was shortened. The changes were reversible with restoring biochemical euthyroidism (P<0·05). Moreover, a significant correlation between some of the parameters and thyroid hormones concentration was demonstrated.
CONCLUSIONS: sHT was associated with significant changes in echocardiographic parameters, which may contribute to increased cardiovascular risk in these patients. The alterations were reversible with restoring biochemical euthyroidism, what supports the necessity of treatment introduction in sHT.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21158893     DOI: 10.1111/j.1365-2265.2010.03957.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  16 in total

1.  A Prospective Comparative Study on Improvement of Hyperthyroid Cardiovascular Dysfunction in Patients Undergoing Total Thyroidectomy Versus Medical Management.

Authors:  S Muthukumar; K Ravikumar; S Dhalapathy; T Gomathy; S Umadevi; D Maruthupandian
Journal:  World J Surg       Date:  2018-05       Impact factor: 3.352

2.  Thyroid and Cardiovascular Disease: Research Agenda for Enhancing Knowledge, Prevention, and Treatment.

Authors:  Anne R Cappola; Akshay S Desai; Marco Medici; Lawton S Cooper; Debra Egan; George Sopko; Glenn I Fishman; Steven Goldman; David S Cooper; Samia Mora; Peter J Kudenchuk; Anthony N Hollenberg; Cheryl L McDonald; Paul W Ladenson
Journal:  Thyroid       Date:  2019-05-13       Impact factor: 6.568

3.  Thyroid and Cardiovascular Disease Research Agenda for Enhancing Knowledge, Prevention, and Treatment.

Authors:  Anne R Cappola; Akshay S Desai; Marco Medici; Lawton S Cooper; Debra Egan; George Sopko; Glenn I Fishman; Steven Goldman; David S Cooper; Samia Mora; Peter J Kudenchuk; Anthony N Hollenberg; Cheryl L McDonald; Paul W Ladenson
Journal:  Circulation       Date:  2019-05-13       Impact factor: 29.690

4.  Changes in cardiac function and structure in newly diagnosed Graves' disease. A conventional and 2D-speckle tracking echocardiography study.

Authors:  K Aroditis; M Pikilidou; E Vourvouri; L Hadjistavri; P Zebekakis; J Yovos; G Efthimiadis; H Karvounis
Journal:  Int J Cardiovasc Imaging       Date:  2016-09-28       Impact factor: 2.357

5.  The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism.

Authors:  Bernadette Biondi; Luigi Bartalena; David S Cooper; Laszlo Hegedüs; Peter Laurberg; George J Kahaly
Journal:  Eur Thyroid J       Date:  2015-08-26

6.  Thyroid hormone and cardiac disease: from basic concepts to clinical application.

Authors:  Iordanis Mourouzis; Francesca Forini; Constantinos Pantos; Giorgio Iervasi
Journal:  J Thyroid Res       Date:  2011-06-19

7.  Treatment of subclinical hyperthyroidism: effect on left ventricular mass and function of the heart using magnetic resonance imaging technique.

Authors:  Peter D Mark; Mikkel Andreassen; Claus L Petersen; Andreas Kjaer; Jens Faber
Journal:  Endocr Connect       Date:  2015-01-07       Impact factor: 3.335

8.  Cardiovascular complications secondary to Graves' disease: a prospective study from Ukraine.

Authors:  Iryna Tsymbaliuk; Dmytro Unukovych; Nataliia Shvets; Andrii Dinets
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

9.  Determinants of thyrotoxic cardiomyopathy recovery.

Authors:  Lucia Oliveros-Ruiz; Maite Vallejo; L Fernando Diez Canseco; Manuel Cárdenas; J Antonio G Hermosillo
Journal:  Biomed Res Int       Date:  2013-09-08       Impact factor: 3.411

10.  The changes in the endothelial function and haemostatic and inflammatory parameters in subclinical and overt hyperthyroidism.

Authors:  Anna Popławska-Kita; Katarzyna Siewko; Beata Telejko; Anna Modzelewska; Janusz Myśliwiec; Robert Milewski; Maria Górska; Małgorzata Szelachowska
Journal:  Int J Endocrinol       Date:  2013-12-03       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.